stocks logo

ACRV

Acrivon Therapeutics Inc
$
1.430
0(0.000%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.480
Open
1.430
VWAP
--
Vol
354.39K
Mkt Cap
44.84M
Low
1.410
Amount
--
EV/EBITDA(TTM)
--
Total Shares
30.88M
EV
-104.80M
EV/OCF(TTM)
--
P/S(TTM)
--
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.567
+4.94%
--
--
-0.580
-1.69%
--
--
-0.583
+12.18%
Estimates Revision
The market is revising Downward the revenue expectations for Acrivon Therapeutics, Inc. (ACRV) for FY2025, with the revenue forecasts being adjusted by -11.11% over the past three months. During the same period, the stock price has changed by -0.69%.
Revenue Estimates for FY2025
Revise Downward
down Image
-11.11%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-11.83%
In Past 3 Month
Stock Price
Go Down
down Image
-0.69%
In Past 3 Month
7 Analyst Rating
up Image
616.78% Upside
Wall Street analysts forecast ACRV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRV is 10.25 USD with a low forecast of 6.00 USD and a high forecast of 19.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
up Image
616.78% Upside
Current: 1.430
sliders
Low
6.00
Averages
10.25
High
19.00
JonesResearch
Buy
to
Hold
downgrade
2025-05-16
Reason
Oppenheimer
Oppenheimer
Outperform
downgrade
$10 -> $9
2025-05-14
Reason
Oppenheimer lowered the firm's price target on Acrivon Therapeutics to $9 from $10 and keeps an Outperform rating on the shares. The firm is adjusting its model after the company's Q1 results and updates on its cash and share position, the analyst tells investors in a research note.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$19
2025-03-28
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$22 → $19
2025-03-26
Reason
Citizens Capital Markets
Silvan Tuerkcan
Buy
Reiterates
$17
2025-03-26
Reason
Cantor Fitzgerald
Li Watsek
Buy
Reiterates
n/a
2025-03-26
Reason

Valuation Metrics

The current forward P/E ratio for Acrivon Therapeutics Inc (ACRV.O) is -0.59, compared to its 5-year average forward P/E of -2.96. For a more detailed relative valuation and DCF analysis to assess Acrivon Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.96
Current PE
-0.59
Overvalued PE
-1.31
Undervalued PE
-4.61

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
45.18
Current PS
346.78
Overvalued PS
183.35
Undervalued PS
-92.99

Financials

Annual
Quarterly
FY2025Q1
YoY :
+22.61%
-21.66M
Operating Profit
FY2025Q1
YoY :
+19.37%
-19.68M
Net Income after Tax
FY2025Q1
YoY :
-30.14%
-0.51
EPS - Diluted
FY2025Q1
YoY :
+9.47%
-19.59M
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
400.5K
USD
1
3-6
Months
3.4M
USD
4
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 7413.3% over the last quarter.
Sold
0-3
Months
2.3M
Volume
1
3-6
Months
30.1K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ACRV News & Events

Events Timeline

2025-05-14 (ET)
2025-05-14
16:31:10
Acrivon Therapeutics reports Q1 EPS (51c), consensus (65c)
select
2025-04-25 (ET)
2025-04-25
08:06:59
Acrivon Therapeutics to present data from analyses of ACR-2316 at AACR
select
2025-04-07 (ET)
2025-04-07
16:07:31
Acrivon appoints Mansoor Raza Mirza as Chief Medical Officer
select
Sign Up For More Events

News

5.0
04-07Newsfilter
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
9.5
03-27Newsfilter
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
9.5
03-27Business Insider
Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c)
Sign Up For More News

FAQ

arrow icon

What is Acrivon Therapeutics Inc (ACRV) stock price today?

The current price of ACRV is 1.43 USD — it has increased 0 % in the last trading day.

arrow icon

What is Acrivon Therapeutics Inc (ACRV)'s business?

arrow icon

What is the price predicton of ACRV Stock?

arrow icon

What is Acrivon Therapeutics Inc (ACRV)'s revenue for the last quarter?

arrow icon

What is Acrivon Therapeutics Inc (ACRV)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Acrivon Therapeutics Inc (ACRV)'s fundamentals?

arrow icon

How many employees does Acrivon Therapeutics Inc (ACRV). have?

arrow icon

What is Acrivon Therapeutics Inc (ACRV) market cap?